FullHope Biomedical
New Taipei City, Taiwan· Est.
Taiwan biotech advancing AI‑enhanced cell immunotherapies for oncology and autoimmunity.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech advancing AI‑enhanced cell immunotherapies for oncology and autoimmunity.
OncologyImmunology
Technology Platform
Cell‑based autologous immunotherapies integrated with an AI‑driven immune function profiling platform for personalized treatment selection.
Opportunities
Leveraging AI‑enhanced immune profiling to accelerate patient‑specific cell therapy development and expand into international collaborations.
Risk Factors
High regulatory and manufacturing complexity for cell products, limited funding for large‑scale trials, and strong competition from established cell‑therapy firms.
Competitive Landscape
Competes with global cell‑therapy companies such as Novartis, Kite, and local Taiwanese biotech firms; differentiation hinges on AI‑driven patient selection and GTP‑certified manufacturing.